RECOG-KRAS Cohort Study
Research type
Research Study
Full title
A Longitudinal Observational Study of Treatment Patterns, Clinical Outcomes and Biomarker Testing in a European cohort of KRAS G12C Non-Small Cell Lung Cancer Patients.
IRAS ID
359148
Contact name
Marie Quinlan
Contact email
Sponsor organisation
Eli Lilly and Company Limited
Duration of Study in the UK
2 years, 6 months, 14 days
Research summary
Non-Small Cell Lung Cancer (NSCLC) remains the leading cause of cancer related mortality worldwide, often diagnosed in late stage which is associated with poorer outcomes. KRAS G12C mutations account for approximately. 15% of all NSCLC cases. \n\n \nWhile targeted therapies for KRAS G12C mutations marks a significant advancement offering a new therapeutic option for difficult-to-treat patients with advanced or metastatic disease, there is still a need for effective treatments for early-stage patients to further improve survival rates and overall prognosis. Understanding real-world diagnostic approaches, treatment patterns and outcomes for KRAS G12C-mutated NSCLC is essential to improve the quality of care for these patients. \n\n \nThis study will provide insights from healthcare institutions who are experienced in managing the treatment of NSCLC across the UK, Germany and Spain into how patients are treated, the adoption of targeted therapies across early and late-stage patients, it will also include insights into clinical outcomes and biomarker testing. \n\nThis is a longitudinal, multi centre observational cohort study, requiring approximately 1200 patients with approximately 400 from the UK, who are adults over the age of 18 and with a confirmed diagnosis of NSCLC including the KRAS G12C mutation between 01 January 2022 until 31 December 2026. \n\nData will be collected from 01 January 2022 through to 31 December 2027. Data collected will be refreshed every 6 months and only retrospective data can be collected. The 6 monthly refreshes allow understanding on the evolution of biomarker testing and treatment patterns of these patients over time.
REC name
North of Scotland Research Ethics Committee 2
REC reference
25/NS/0073
Date of REC Opinion
8 Jul 2025
REC opinion
Unfavourable Opinion